ホーム › 肝臓がん（肝細胞がん） › イリノイ州
イリノイ州における肝臓がん（肝細胞がん）の臨床試験
イリノイ州内の拠点で、肝臓がん（肝細胞がん）に関する20件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
- Memorial Hospital, Shiloh
- Siteman Cancer Center - Shiloh, Shiloh
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07227012National Liver Cancer Screening Trial
- Northwestern University, Chicago
被験者募集中第4相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06084234A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
- Local Institution - 0107, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07291076Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
- OSF St. Francis Medical Center, Peoria
被験者募集中第2相
18歳〜100歳 · 全性別 · 2026/09/23更新 · NCT07219459A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- City of Hope Chicago Cancer Center, Zion
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06427941Defining the Ablative Dose for Y-90 TARE
- Northwestern University, Chicago
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT07586046Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- RUSH University Medical Center, Chicago
- University of Chicago, Chicago
被験者募集中観察研究
22歳以上 · 全性別 · 2026/09/11更新 · NCT06486454Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Chicago
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06921785Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Lurie Children's Hospital-Chicago, Chicago
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle at The Riverfront, Danville
- 他6件
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/17更新 · NCT07166406A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
- Carle Cancer Center NCI Community Oncology Research Program, Urbana
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05168163DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
- Rush University Medical Center, Chicago
被験者募集中観察研究
18歳以上 · 全性別 · 2026/07/21更新 · NCT07717437Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer
- Northwestern University, Chicago
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/25更新 · NCT07042919A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/17更新 · NCT06600321Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk
- Northwestern University, Chicago
- Northwestern Medicine Kishwaukee Hospital, DeKalb
- Northwestern Medicine Delnor Hospital, Geneva
- 他4件
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/26更新 · NCT05620771Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- University of Chicago Medical Center, Chicago
- Methodist Medical Center of Illinois, Peoria
被験者募集中第4相
18歳〜64歳 · 全性別 · 2026/01/22更新 · NCT04373564SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chicago
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774The Dragon PLC Trial (DRAGON-PLC)
- Rush University Medical Center, Chicago
被験者募集中
18歳以上 · 全性別 · 2025/05/15更新 · NCT06914648ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。